Elisabetta Buommino Selected Research

3-O-methylfunicone

8/2012	Cell-growth and migration inhibition of human mesothelioma cells induced by 3-O-methylfunicone from Penicillium pinophilum and cisplatin.
11/2007	3-O-methylfunicone produced by penicillium pinophilum affects cell motility of breast cancer cells, downregulating alphavbeta5 integrin and inhibiting metalloproteinase-9 secretion.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Elisabetta Buommino Research Topics

Disease

13	Infections 10/2021 - 01/2002
7	Neoplasms (Cancer) 01/2017 - 11/2007
5	Inflammation (Inflammations) 01/2024 - 12/2011
2	Persistent Infection 01/2024 - 01/2017
2	Mesothelioma 01/2017 - 08/2012
2	Melanoma (Melanoma, Malignant) 12/2013 - 10/2009
2	Adenocarcinoma 12/2012 - 05/2004
1	Bacterial Infections (Bacterial Infection) 01/2024
1	Cystic Fibrosis (Mucoviscidosis) 01/2024
1	Dysbiosis 06/2023
1	Bronchial Diseases 02/2023
1	Wounds and Injuries (Trauma) 01/2021
1	Seizures (Absence Seizure) 01/2021
1	Coinfection 08/2020
1	Candidiasis (Moniliasis) 07/2018
1	Urinary Tract Infections (Urinary Tract Infection) 02/2017
1	Experimental Melanoma 12/2013
1	Malignant Mesothelioma 08/2012
1	Acantholysis 09/2011
1	Psoriasis (Pustulosis Palmaris et Plantaris) 07/2009
1	Periodontal Pocket (Periodontal Pockets) 09/2008
1	Periodontitis 09/2008
1	Bartonella Infections (Bartonellosis) 07/2008
1	Breast Neoplasms (Breast Cancer) 11/2007
1	Stomach Neoplasms (Stomach Cancer) 05/2004

Drug/Important Bio-Agent (IBA)

2	Antimicrobial PeptidesIBA 10/2021 - 08/2020
2	Peptides (Polypeptides)IBA 08/2020 - 09/2008
2	Proteins (Proteins, Gene)FDA Link 07/2017 - 01/2002
2	CytokinesIBA 01/2017 - 12/2015
2	OsteopontinIBA 01/2017 - 07/2009
2	Interleukin-8 (Interleukin 8)IBA 12/2015 - 04/2013
2	Interleukin-6 (Interleukin 6)IBA 12/2015 - 04/2013
2	Matrix Metalloproteinases (MMPs)IBA 12/2012 - 11/2007
2	3-O-methylfuniconeIBA 08/2012 - 11/2007
2	Metalloproteases (Metalloproteinases)IBA 10/2009 - 11/2007
1	Complement System Proteins (Complement)IBA 01/2024
1	Virulence Factors (Pathogenicity Factors)IBA 01/2024
1	Oxidopamine (6 Hydroxydopamine)IBA 06/2023
1	Ceftriaxone (Ceftriaxon)FDA LinkGeneric 06/2023
1	DiureticsIBA 02/2023
1	Oxacillin (Prostaphlin)FDA LinkGeneric 10/2021
1	Methicillin (Metin)FDA Link 01/2021
1	abietic acidIBA 01/2021
1	temporinIBA 08/2020
1	FlavonoidsIBA 01/2019
1	LignansIBA 01/2019
1	PolyphenolsIBA 01/2019
1	Biomarkers (Surrogate Marker)IBA 01/2017
1	DefensinsIBA 01/2016
1	SaltsIBA 01/2016
1	Peptide Hydrolases (Proteases)FDA Link 01/2016
1	Interleukin-10 (Interleukin 10)IBA 12/2015
1	matrigelIBA 12/2014
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 12/2013
1	Simvastatin (Zocor)FDA LinkGeneric 12/2013
1	Cisplatin (Platino)FDA LinkGeneric 08/2012
1	AsbestosIBA 08/2012
1	AV119IBA 12/2011
1	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 09/2011
1	artemisinin (artemisinine)IBA 10/2009
1	Integrin beta3 (GPIIIa)IBA 10/2009
1	Glycoproteins (Glycoprotein)IBA 07/2009
1	beta-DefensinsIBA 09/2008
1	1- hydroxy- 2- oxo- 3,3- bis(2- aminoethyl)- 1- triazeneIBA 07/2008
1	omega-N-Methylarginine (NG Monomethyl L Arginine)IBA 07/2008
1	oxidized low density lipoproteinIBA 07/2008
1	LectinsIBA 07/2008
1	erucylphosphocholineIBA 07/2008
1	Phosphotransferases (Kinase)IBA 07/2008
1	SurvivinIBA 11/2007
1	integrin alphaVbeta5IBA 11/2007
1	IntegrinsIBA 11/2007
1	alpha-MSHIBA 12/2004
1	Placenta Growth FactorIBA 05/2004
1	Interferon-gamma (Interferon, gamma)IBA 05/2004

Therapy/Procedure

2	Therapeutics 07/2018 - 11/2007
1	Fecal Microbiota Transplantation 01/2021
1	Catheters 02/2017
1	Immunomodulation 01/2016